ZIM
DGX icon

Zacks Investment Management’s Quest Diagnostics DGX Stock Holding History

Zacks Investment Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,332
Closed -$4.15M – 661
2023
Q1 		$4.15M Buy
29,332
+477
+2% +$68.2K 0.06% 202
2022
Q4 		$4.51M Sell
28,855
-201
-0.7% -$28.9K 0.06% 197
2022
Q3 		$3.56M Buy
+29,056
New +$3.83M 0.06% 205

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Zacks Investment Management's DGX Position: Q2 2023 in Review

Zacks Investment Management sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 29,332 shares — an estimated $4.15M sold.

Zacks Investment Management first reported a position in DGX in Q3 2022 and held it in 3 quarters. The position peaked at $4.51M in Q4 2022. 818 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

  • Zacks Investment Management reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Zacks Investment Management sold 29,332 Quest Diagnostics shares in Q2 2023, an estimated $4.15M.
  • Zacks Investment Management first reported a position in Quest Diagnostics in Q3 2022 and held it in 3 quarters.
  • Zacks Investment Management's Quest Diagnostics position peaked at $4.51M in Q4 2022.
  • 818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Zacks Investment Management's 13F filing for Q2 2023, filed 15 Aug 2023.